MPERIA -THE CD36 THERAPEUTICS DEVELOPMENT COMPANY
Sustained leadership position for clinical development of therapeutics for CD36-mediated diseases.
WORLD-CLASS BOARDS & MGMT
CD36 MODULATES MACROPHAGES
Mperia's team have spent >20 years understanding the CD36 receptor and have developed highly selective CD36-receptor mediated ligands to re-program M1 macrophages from a pro- to anti-inflammatory action.
We have carefully developed and tested a series of potent, short-chain peptides for high specificity binding of the CD36 receptor, to promote the best therapeutic of all, the patient’s own innate immune system.
The confirmed mechanism-of-action promotes macrophage rebalancing to an anti-inflammatory action. Leading clinical programs are described below: